However, we noted differences by mouse strain for overall outcome: while 40% of immunocompetent mice bearing CD95L knockout tumors achieved long-term survival (Fig. 5c) and did not develop neurologic symptoms after tumor rechallenge (data not shown), none of the CD95L knockout cell-bearing immunodeficient mice survived for more than 60 days after glioma cell implantation (Fig. 5d). This evidence concerns the gene FASLG and neoplasm.